AstraZeneca PLC (NASDAQ: AZN) reported second-quarter earnings that surpassed expectations, driven by strong sales of its blockbuster cancer drugs. The market's attention is now turning to the company's pipeline of next-generation oncology treatments.

On Monday, the British pharmaceutical giant announced that revenue for the second quarter rose 5% on a constant currency basis to $15.38 billion, slightly below the market consensus of $15.39 billion. Adjusted earnings per share increased by 18% to $2.63, exceeding the analyst estimate of $2.48. Sales of the breast cancer drug Enhertu saw significant growth.

AstraZeneca PLC is renowned for its robust presence in the oncology field, having launched several blockbuster drugs, including Tagrisso and Imfinzi. However, investors are now increasingly focused on whether the company can sustain this success, with key clinical trial data from multiple programs expected to be released in the second half of the year.

AstraZeneca PLC continues to forecast low double-digit percentage growth in core earnings per share for 2026, alongside mid-to-high single-digit total revenue growth. For 2025, the company anticipates revenue and profit growth of approximately 8% and 11%, respectively, year-over-year.

AstraZeneca's stock has declined 8% year-to-date, triggered by disappointing clinical data for its cardiovascular drug, Wainua. Earlier, management had signaled a positive outlook for the drug, making the clinical failure a significant disappointment for the market. The company, historically known for its rigorous clinical trial standards, rarely sees late-stage drug failures, and this setback has notably damaged market confidence.